视网膜静脉阻塞治疗的全球市场规模、份额和增长分析：按疾病类型和治疗方法- 行业预测（2024-2031）

2022年全球视网膜静脉阻塞治疗市场规模将为139.2亿美元，从2023年的154.1亿美元增长到2031年的347.5亿美元，预计在预测期内（2024年~2031年）将增长年复合增长率为10.70%。

由于 RVO 盛行率上升以及易患该疾病的老年人口不断增加，视网膜静脉阻塞 (RVO) 治疗市场正在经历显着增长。 RVO 是一种常见的视网膜血管疾病，如果不及时治疗，会带来视力丧失和失明的风险。该市场提供多种治疗选择，包括药物、雷射治疗和手术干预，旨在增加血液循环、减少黄斑部水肿和防止视力丧失。市场按治疗类型、最终用户和地区进行细分，抗 VEGF 药物作为控制血管增生和黄斑部水肿的有前景的选择脱颖而出。特别是在北美和欧洲，医疗基础设施发达，新治疗方法较早推出。由于医疗保健意识的提高和医疗设施的改善，亚太地区也在经历成长。研发投资的增加、诊断技术的进步以及製药公司和研究机构之间的合作等因素正在推动创新治疗方法的创造。此外，预计市场将进一步关注个人化医疗和以患者为中心的方法。随着对有效 RVO 治疗的需求增加，製造商和医疗保健提供者正在合作提供更容易获得和更有效的解决方案，旨在改善受这种疾病影响的人们的生活品质。Masu。

目录

执行摘要

• 市场概况
• 命运之轮

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模估算
• 市场假设与限制

母市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

主要市场考察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• Start-Ups分析
• 原料分析
• 创新矩阵
• 研发线产品分析
• 总体经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管环境
• 波特的分析
• 对未来中断的特殊考虑

全球视网膜静脉阻塞治疗市场：依疾病类型

• 市场概况
• 视网膜中央静脉阻塞（CRVO）
• 视网膜分支静脉阻塞症（BRVO）

视网膜静脉阻塞治疗的全球市场：治疗方法

• 市场概况
• 抗血管内皮生长因子（抗VEGF）
• 皮质类固醇药物
• 其他的

全球视网膜静脉阻塞治疗市场规模：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2021年）
• 主要市场参与者所采取的策略
• 关键成功策略
• 近期市集活动
• 主要企业市场占有率（2021年）

主要企业简介

• Alcon
• Pfizer Inc.
• Genentech
• Regeneron Pharmaceuticals Inc.
• Allergan plc
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Sanofi
• Thrombogenics Inc.
• Acucela Inc.
• Clearside Biomedical Inc
• EyePoint Pharmaceuticals Inc.
• Sirnaomics Inc.
• Astellas Pharma Inc.
• Bellus Health Inc.

Global Retinal Vein Occlusion Treatment Market size was valued at USD 13.92 billion in 2022 and is poised to grow from USD 15.41 billion in 2023 to USD 34.75 billion by 2031, growing at a CAGR of 10.70% during the forecast period (2024-2031).

The treatment market for retinal vein occlusion (RVO) is experiencing significant growth, attributed to the rising prevalence of RVO and the expanding elderly population susceptible to this condition. RVO, a common retinal vascular disorder, poses a risk of vision impairment and blindness if not promptly addressed. This market offers diverse treatment options, including medications, laser therapy, and surgical interventions, all aimed at enhancing blood circulation, reducing macular edema, and preventing vision loss. The market is segmented based on treatment type, end-user, and region, with anti-VEGF medications standing out as a prominent choice for controlling abnormal blood vessel growth and macular edema. The market's expansion is propelled by the increasing acceptance of advanced therapies and the growing incidence of RVO cases, particularly in North America and Europe, where well-established healthcare infrastructure and early adoption of novel treatments are evident. The Asia-Pacific region is also witnessing growth, fueled by heightened healthcare awareness and improved medical facilities. Factors such as augmented investment in research and development, advancements in diagnostic techniques, and collaborative efforts among pharmaceutical companies and research institutions are fostering the creation of innovative treatment methods. Furthermore, a rising emphasis on personalized medicine and patient-centric approaches is anticipated to propel the market forward. With the demand for effective RVO treatments on the rise, manufacturers and healthcare providers are collaborating to deliver more accessible and efficient solutions, aiming to enhance the quality of life for individuals affected by this condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Vein Occlusion Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Vein Occlusion Treatment Market Segmental Analysis

The retinal vein occlusion treatment market is segmented on the basis of disease type, treatment, end-user, and regional. Based on Disease Type the market is segmented as, Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO). Based on Treatment the market is segmented as, Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, And Others. Based on End-user the market is segmented as, Hospital & Clinics, Research and Academics, Others. Based on Regional the market is segmented as, North America, Asia Pacific, Latin America.

Drivers of the Global Retinal Vein Occlusion Treatment Market

The growth of the retinal vein occlusion market is propelled by various factors, including the increasing global prevalence of eye diseases, a rising elderly population, enhanced comprehension of eye disorders, strengthened healthcare infrastructure, technological progress, and the introduction of novel therapies. The market's momentum is further augmented by a robust pipeline and recent approvals of new drugs. With a growing number of retinal vein occlusion cases and ongoing research into treatment molecules, the effectiveness of retinal vein occlusion therapy is witnessing an upward trend. This is supported by a strong pipeline and recent drug clearances, presenting significant opportunities for the adoption of innovative retinal vein occlusion therapeutics and contributing to the market's expansion.

Restraints in the Global Retinal Vein Occlusion Treatment Market

The bioresorbable scaffolds market encounters a hurdle due to a scarcity of extensive long-term clinical data. Additional assessment is essential to conclusively determine the efficacy and safety of bioresorbable scaffold implants in comparison to traditional stents. Evaluating the outcomes will contribute to a more comprehensive understanding of their performance over an extended period.

Market Trends of the Global Retinal Vein Occlusion Treatment Market

The rising occurrence of retinal vein occlusion, especially in the elderly demographic, is fueling the need for viable treatment solutions. With the global population aging, there is a projected increase in the prevalence of this condition, which is anticipated to contribute to the expansion of the market.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Retinal Vein Occlusion Treatment Market by Disease Type

• Market Overview
• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Global Retinal Vein Occlusion Treatment Market by Treatment

• Market Overview
• Anti-vascular Endothelial Growth Factor (Anti-VEGF)
• Corticosteroid Drugs
• and Others

Global Retinal Vein Occlusion Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Alcon
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thrombogenics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acucela Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bellus Health Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments